Delay in Insurance Approval of Biologic Therapy Dose Escalation Is Associated With Increased Disease Activity in Patients With Inflammatory Bowel Disease

被引：0

作者：

Shah, Nisha ^{[1
]}

Cherry, Laura ^{[1
]}

Zuckerman, Autumn ^{[1
]}

Vimalathas, Praveen ^{[1
]}

Choi, Leena ^{[1
]}

Donoho, Charles A. ^{[1
]}

Pabla, Baldeep ^{[1
]}

Scoville, Elizabeth ^{[1
]}

Dalal, Robin ^{[1
]}

Beaulieu, Dawn ^{[1
]}

Schwartz, David ^{[1
]}

Horst, Sara ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S833

引用

页码：S385 / S385

页数：1

共 50 条

[31] THE IMPACT OF DELAY BETWEEN BIOLOGIC PRESCRIPTION AND THERAPY INITIATION ON CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
Agrawal, Manasi
Tepler, Adam
Hong, Simon
Advani, Rashmi
Lukin, Dana J.
GASTROENTEROLOGY, 2019, 156 (06) : S142 - S142
[32] De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease
Miyatani, Yusuke
Kobayashi, Taku
GUT AND LIVER, 2023, 17 (02) : 181 - 189
[33] The Impact of Delay Between Biologic Prescription and Therapy Initiation on Clinical Outcomes in Inflammatory Bowel Disease Patients
Agrawal, Manasi
Tepler, Adam
Hong, Simon
Advani, Rashmi
Lukin, Dana
GASTROENTEROLOGY, 2019, 157 (01) : E23 - E23
[34] Predicting response to dose escalation in patients with inflammatory bowel disease with secondary loss of response to biological therapy
Tambakis, G.
Sebastian, T.
Sun, G.
Reynen, T.
Van Wees, M.
Bhoopal, A.
Splatt, L.
Cunningham, G.
Shelton, E.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 111 - 111
[35] Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
Rubin De Celix, C.
Ricart, E.
Martin-Arranz, M. D.
de Francisco, R.
Barrio, J.
Mesonero, F.
Gomollon, F.
de Castro, L.
Ramos, L.
Garcia-Lopez, S.
Arias, L.
Manosa, M.
Iglesias, E.
Calvet, X.
Pascual, I.
Casanova, M. J.
Perez-Calle, J. L.
Giordano, A.
Sierra, M.
Vera, I.
Navarro-Llavat, M.
Lorente, R.
Piqueras, M.
Rivero, M.
Guardiola, J.
Esteve, M.
Coronel, A. Fuentes
Rodriguez-Lago, I.
Ponferrada, A.
Ber, Y.
Tardillo, C.
Marquez, L.
Carpio, D.
Taxonera, C.
Bermejo, F.
Busquets, D.
Camps, B.
Domenech, E.
Chaparro, M.
Gisbert, J. P.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1557 - I1559
[36] INFECTIOUS COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECIEVING BIOLOGIC THERAPY
Ochoa, C. D.
Rajaram, P.
Tanukonda, S.
Sadikot, R. T.
JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (02) : 679 - 680
[37] THE EFFECT OF INFLIXIMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTIBODIES TO INFLIXIMAB
Tun, Gloria S. Z.
Marshall, Laura
Thompson, Laura
Campbell, Rebecca
Hale, Melissa F.
Chew, Thean S.
Brooks, Alenka J.
Robinson, Kerry
Lobo, Alan J.
GUT, 2019, 68 : A61 - A62
[38] EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Shivashankar, Raina
Ladd, Antonio H. Mendoza
Grace, Rory
Aberra, Faten
Lichtenstein, Gary R.
GASTROENTEROLOGY, 2017, 152 (05) : S77 - S77
[39] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
Sierra Morales, M.
Birdi, S.
Samaan, M. A.
Brown-Clarke, C.
Duncan, J.
Stanton, A.
Koumoutsos, I.
Anderson, S.
Ray, S.
Mawdsley, J.
Sanderson, J.
Irving, P. M.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452
[40] The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab
Tun, Gloria S. Z.
Robinson, Kerry
Marshall, Laura
Wright, Alison
Thompson, Laura
Wild, Graeme
Sargur, Ravishankar
Brooks, Alenka J.
Hale, Melissa F.
Chew, Thean S.
Lobo, Alan J.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 295 - 301

← 1 2 3 4 5 →